Biochemistry, Genetics and Molecular Biology
Action Potential
27%
Allele
72%
Amino Acids
21%
Bigeminy
18%
Bioinformatics
54%
C-Terminus
10%
Calcium
54%
Cardiac Arrest
9%
Cardiac Electrophysiology
13%
Carvedilol
18%
Catecholaminergic Polymorphic Ventricular Tachycardia
100%
Channelopathy
13%
Classification
54%
Computer Model
10%
Data Base
32%
Electrochemical Gradient
27%
Emotion
18%
Emotional Stress
18%
Exercise
18%
Flow
13%
Genetic Divergence
54%
Genetic Screening
18%
Genotyping
18%
Homeostasis
54%
Induced Pluripotent Stem Cell
9%
Ion Current
27%
Ion Transport
10%
Life
18%
Medical Genomics
10%
Messenger RNA
9%
Minigene
54%
Minor Allele Frequency
10%
Missense Mutation
18%
Molecular Genetics
18%
Mutant
72%
Mutation
54%
Nebivolol
18%
Phenotype
10%
Position
21%
Protein
10%
Reduction (Chemistry)
18%
RNA
54%
Ryanodine Receptor
9%
Ryanodine Receptor 2
20%
Sarcolemma
13%
Screening
54%
Sequence Database
10%
Sleep
21%
Sudden Cardiac Death
18%
Wild Type
54%
Medicine and Dentistry
Adverse Outcome
54%
Age
18%
Attention
18%
Calcium Signaling
9%
Cardiomyocyte
9%
Cardiovascular Risk
54%
Carvedilol
18%
Catecholaminergic Polymorphic Ventricular Tachycardia
45%
Deterioration
36%
Diagnosis
36%
Diseases
18%
Emotion
18%
Emotional Stress
18%
Exercise
18%
Faintness
36%
Family
54%
Feeding
18%
Frailty
18%
Genetic Screening
18%
Genotype
18%
Heart Arrest
9%
Heart Ventricle Arrhythmia
9%
Induced Pluripotent Stem Cell
9%
Isoprenaline
9%
Isotopes of Calcium
54%
Life
72%
Malnutrition
36%
Messenger RNA
9%
Metabolism
18%
Missense Mutation
18%
Mutant
18%
Patient
36%
Physical Activity
18%
Receptor Gene
9%
Ryanodine Receptor 2
9%
Screening
54%
Serositis
18%
Sibling
18%
Sudden Cardiac Death
18%
Sudden Death
54%
Sudden Unexpected Death in Epilepsy
18%
Survival
18%
Therapeutic Procedure
27%
Weight Loss
18%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Outcome
54%
Atrial Fibrillation
54%
Cardiovascular Risk
54%
Clinical Trial
6%
Complication
6%
Dabigatran
54%
Deterioration
36%
Drug
18%
Frailty
18%
Inflammation
18%
Malnutrition
36%
Observational Study
6%
Survival
18%
Warfarin
54%